Matches in Nanopublications for { ?s ?p "[To explore mechanisms contributing to the clinical heterogeneity of systemic mastocytosis (SM) and to suboptimal responses to diverse therapies, we analyzed 39 KIT D816V mutated patients with indolent SM (n = 10), smoldering SM (n = 2), SM with associated clonal hematologic nonmast cell lineage disorder (SM-AHNMD, n = 5), and aggressive SM (n = 15) or mast cell leukemia (n = 7) with (n = 18) or without (n = 4) AHNMD for additional molecular aberrations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- NP750840.RA9YL04sz_C1kxB1j3dBwewAsQlTdwSuGrpx6lXLeaNHY130_assertion description "[To explore mechanisms contributing to the clinical heterogeneity of systemic mastocytosis (SM) and to suboptimal responses to diverse therapies, we analyzed 39 KIT D816V mutated patients with indolent SM (n = 10), smoldering SM (n = 2), SM with associated clonal hematologic nonmast cell lineage disorder (SM-AHNMD, n = 5), and aggressive SM (n = 15) or mast cell leukemia (n = 7) with (n = 18) or without (n = 4) AHNMD for additional molecular aberrations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP750840.RA9YL04sz_C1kxB1j3dBwewAsQlTdwSuGrpx6lXLeaNHY130_provenance.
- assertion description "[To explore mechanisms contributing to the clinical heterogeneity of systemic mastocytosis (SM) and to suboptimal responses to diverse therapies, we analyzed 39 KIT D816V mutated patients with indolent SM (n = 10), smoldering SM (n = 2), SM with associated clonal hematologic nonmast cell lineage disorder (SM-AHNMD, n = 5), and aggressive SM (n = 15) or mast cell leukemia (n = 7) with (n = 18) or without (n = 4) AHNMD for additional molecular aberrations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[To explore mechanisms contributing to the clinical heterogeneity of systemic mastocytosis (SM) and to suboptimal responses to diverse therapies, we analyzed 39 KIT D816V mutated patients with indolent SM (n = 10), smoldering SM (n = 2), SM with associated clonal hematologic nonmast cell lineage disorder (SM-AHNMD, n = 5), and aggressive SM (n = 15) or mast cell leukemia (n = 7) with (n = 18) or without (n = 4) AHNMD for additional molecular aberrations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP525337.RAqLImczQqAsgRExejYrAIn2r4Jgo86GQURdJ0Hwh7OEQ130_assertion description "[To explore mechanisms contributing to the clinical heterogeneity of systemic mastocytosis (SM) and to suboptimal responses to diverse therapies, we analyzed 39 KIT D816V mutated patients with indolent SM (n = 10), smoldering SM (n = 2), SM with associated clonal hematologic nonmast cell lineage disorder (SM-AHNMD, n = 5), and aggressive SM (n = 15) or mast cell leukemia (n = 7) with (n = 18) or without (n = 4) AHNMD for additional molecular aberrations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP525337.RAqLImczQqAsgRExejYrAIn2r4Jgo86GQURdJ0Hwh7OEQ130_provenance.
- NP840300.RAKXdKIrFBg434RVqPCTAy7CWkwAeJkAV_SUwPgmMjXDU130_assertion description "[To explore mechanisms contributing to the clinical heterogeneity of systemic mastocytosis (SM) and to suboptimal responses to diverse therapies, we analyzed 39 KIT D816V mutated patients with indolent SM (n = 10), smoldering SM (n = 2), SM with associated clonal hematologic nonmast cell lineage disorder (SM-AHNMD, n = 5), and aggressive SM (n = 15) or mast cell leukemia (n = 7) with (n = 18) or without (n = 4) AHNMD for additional molecular aberrations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP840300.RAKXdKIrFBg434RVqPCTAy7CWkwAeJkAV_SUwPgmMjXDU130_provenance.
- NP1103675.RAZKzz-GFbfLGAqKX4jXphBlaorHf7fszxSxoqvz0v05Y130_assertion description "[To explore mechanisms contributing to the clinical heterogeneity of systemic mastocytosis (SM) and to suboptimal responses to diverse therapies, we analyzed 39 KIT D816V mutated patients with indolent SM (n = 10), smoldering SM (n = 2), SM with associated clonal hematologic nonmast cell lineage disorder (SM-AHNMD, n = 5), and aggressive SM (n = 15) or mast cell leukemia (n = 7) with (n = 18) or without (n = 4) AHNMD for additional molecular aberrations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1103675.RAZKzz-GFbfLGAqKX4jXphBlaorHf7fszxSxoqvz0v05Y130_provenance.
- NP1103674.RA6H1gTg28KBSeusYboPJHpIXYKc_GBud6265TbxjVfx8130_assertion description "[To explore mechanisms contributing to the clinical heterogeneity of systemic mastocytosis (SM) and to suboptimal responses to diverse therapies, we analyzed 39 KIT D816V mutated patients with indolent SM (n = 10), smoldering SM (n = 2), SM with associated clonal hematologic nonmast cell lineage disorder (SM-AHNMD, n = 5), and aggressive SM (n = 15) or mast cell leukemia (n = 7) with (n = 18) or without (n = 4) AHNMD for additional molecular aberrations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1103674.RA6H1gTg28KBSeusYboPJHpIXYKc_GBud6265TbxjVfx8130_provenance.